Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.

Leona Plum-MörschelOliver KleinGursharan SinghSundara Moorthi Nainar MurugesanAshwani MarwahNirant SharmaJayanti PandaSubramanian LoganathanGopu Chandrasekharan LakshmiSandeep N Athalye

Published in: Diabetes, obesity & metabolism (2022)

PK/PD equivalence was demonstrated between Biocon's Insulin-70/30 and HUMULIN-70/30 in healthy subjects. Treatment with Biocon's Insulin-70/30 and HUMULIN-70/30 was well tolerated.

Keyphrases

type diabetes
glycemic control
recombinant human
drug delivery
metabolic syndrome
combination therapy
replacement therapy